Information Journal Paper
APA:
Copy. (2017). ABBV-399, a c-Met antibody-drug conjugate that targets both MET-Amplified and c-Met-Overexpressing tumors, irrespective of MET pathway dependence. CLINICAL CANCER RESEARCH, 23(4), 992-1000. SID. https://sid.ir/paper/747520/en
Vancouver:
Copy. ABBV-399, a c-Met antibody-drug conjugate that targets both MET-Amplified and c-Met-Overexpressing tumors, irrespective of MET pathway dependence. CLINICAL CANCER RESEARCH[Internet]. 2017;23(4):992-1000. Available from: https://sid.ir/paper/747520/en
IEEE:
Copy, “ABBV-399, a c-Met antibody-drug conjugate that targets both MET-Amplified and c-Met-Overexpressing tumors, irrespective of MET pathway dependence,” CLINICAL CANCER RESEARCH, vol. 23, no. 4, pp. 992–1000, 2017, [Online]. Available: https://sid.ir/paper/747520/en